ReviewFrontiers in cell and developmental biology2025
Multidimensional mechanisms of quercetin in diabetic kidney disease.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ultrastructural alterations of cementum and periodontal ligament in fluorosed teeth: an SEM and EDS study.Odontology · 2026Article
- Rho/PAK signaling: a key driver of anthracycline and taxane resistance in breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- The dual role of ion channels in diabetic kidney disease: a translational paradigm for biomarkers and target discovery - reviews and prospects.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin is a flavonoid compound that has demonstrated substantial potential in the treatment of diabetic kidney disease (DKD). However, there is still a lack of systematic research on the exact mechanism of action of quercetin. This review discusses the druggability, molecular targets, and signaling pathways of quercetin in DKD treatment. We retrieved the latest research on the pharmacological effects and mechanisms related to quercetin from PubMed and Scopus as of June 2025 (2012-2025). Evidence suggests that quercetin has the potential to eliminate senescent cells in DKD. Network pharmacology was used to predict the targets and pathways of quercetin in targeting cellular senescence to treat DKD. Using on existing research, it was further confirmed that quercetin can effectively act on hub target and pathway. The mechanism of quercetin therapy in DKD was summarized from three dimensions: inflammation, oxidative stress, and cell death. This review highlights the potential of quercetin for treating DKD by providing a biological basis for its mechanism of action and its use as a senolytic drug for this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.